As It Aims To Enter Clinic, Eleven Bio Adds Top Management
This article was originally published in The Pink Sheet Daily
Executive Summary
With an ophthalmological candidate on the way, the well-funded startup taps two new execs to replace investor Third Rock's interim leadership.
You may also be interested in...
Eleven Biotherapeutics Gets Rocking As Next Generation Biologics Firm
Proceeds from a $35 million Series A financing, led by Flagship Ventures and Third Rock Ventures, will be used to build R&D and business development teams.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.